S. 3311 - American Made Pharmaceuticals Act of 2023 - Support for policies that encourage keeping the different elements of the prescription drug supply chain in the country to support better access to lifesaving medications and expand the number of quality jobs in the United States.
Issues related to drug shortages in the United States and the role biosimilars can play.
Issues related to cancer care and developing both biosimilar and novel treatments to fight disease.
Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs.
Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Duration: August 27, 2015
to
December 31, 2023
General Issues: Pharmacy , Health Issues , Medicare/Medicaid
Spending: about $1,820,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
Nathanson+Hauck terminated an engagement in which they represented Coherus Biosciences on Dec. 31, 2023.
Original Filing: 301521052.xml
Lobbying Issues
S. 3311 - American Made Pharmaceuticals Act of 2023 - Support for policies that encourage keeping the different elements of the prescription drug supply chain in the country to support better access to lifesaving medications and expand the number of quality jobs in the United States.
Issues related to drug shortages in the United States and the role biosimilars can play.
Issues related to cancer care and developing both biosimilar and novel treatments to fight disease.
Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs.
Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $50,000. The report was filed on Oct. 7, 2023.
Original Filing: 301498384.xml
Lobbying Issues
Issues related to drug shortages in the United States and the role biosimilars can play.
Issues related to cancer care and developing both biosimilar and novel treatments to fight disease.
Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs.
Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $50,000. The report was filed on July 5, 2023.
Original Filing: 301473317.xml
Lobbying Issues
Issues related to drug shortages in the United States and the role biosimilars can play.
Issues related to cancer care and developing both biosimilar and novel treatments to fight disease.
Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs.
Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $50,000. The report was filed on April 18, 2023.
Original Filing: 301455129.xml
Lobbying Issues
Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs.
Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $50,000. The report was filed on Jan. 17, 2023.
Original Filing: 301429256.xml
Lobbying Issues
H.R. 2617 - The Consolidated Appropriations Act for FY 2023 - Support for policy and guidance related to the treatment of American made biosimilar and generic medications as part of Buy American policies.
PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program.
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US.
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $50,000. The report was filed on Oct. 8, 2022.
Original Filing: 301401994.xml
Lobbying Issues
PL 117-169 - The Inflation Reduction Act of 2022 - Support for policies focused on advancing the use of biosimilars in the Medicare program.
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US.
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on July 4, 2022.
Original Filing: 301377195.xml
Lobbying Issues
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US.
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on April 19, 2022.
Original Filing: 301361635.xml
Lobbying Issues
S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US.
H.R. 5376 - Build Back Better Act - Continued advocacy for issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 11, 2022.
Original Filing: 301321114.xml
Lobbying Issues
H.R. 5376 - Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications
Work to advance policies that support companies that fully manufacture products in the USA.
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Oct. 11, 2021.
Original Filing: 301297664.xml
Lobbying Issues
Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications
Work to advance policies that support companies that fully manufacture products in America.
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on July 15, 2021.
Original Filing: 301276854.xml
Lobbying Issues
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on April 14, 2021.
Original Filing: 301253249.xml
Lobbying Issues
S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system.
Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices.
Policies to help grow the biosimilars marketplace in the United States.
Policies focused on improving cancer care through access to affordable treatments.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 12, 2021.
Original Filing: 301230035.xml
Lobbying Issues
Most Favored Nation Prescription Drug Regulations and Executive Orders promulgated by the Administration and its impact on biosimilars.
P.L. 116-260/H.R. 133 - Consolidated Appropriations Act of 2021 - Issues related to the fight against COVID-19 and coverage of medications indirectly related to the treatment of cancer patients during the pandemic as well as provisions designed to bolster the nation's biosimilars marketplace.
H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues.
The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues.
H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders.
Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.
H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place.
H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards and coverage in the 340b program.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Oct. 12, 2020.
Original Filing: 301208698.xml
Lobbying Issues
H.R. 8406 - The HEROES Act (modified) - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues.
The Senate HEALS Act - Issues related to coverage of treatment and coverage of Covid-19 related and adjacent medical issues.
H.R. 8319 - Continuing Appropriations Act of 2021 - Issues related to the funding of health care extenders.
Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States.
H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.
H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place.
H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on July 3, 2020.
Original Filing: 301185285.xml
Lobbying Issues
Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States.
H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans.
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.
H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place.
H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on April 12, 2020.
Original Filing: 301165531.xml
Lobbying Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients.
H.R. 6201 - Families First Coronavirus Response Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 748 - The CARES Act - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses.
H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place.
H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 8, 2020.
Original Filing: 301103838.xml
Lobbying Issues
H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place.
H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Oct. 13, 2019.
Original Filing: 301064938.xml
Lobbying Issues
H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace.
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on July 11, 2019.
Original Filing: 301044380.xml
Lobbying Issues
S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States.
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on April 9, 2019.
Original Filing: 301023581.xml
Lobbying Issues
Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 13, 2019.
Original Filing: 301004038.xml
Lobbying Issues
Executive and Legislative initiatives to allow the biosimilars market place to succeed in the United States.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Oct. 15, 2018.
Original Filing: 300985086.xml
Lobbying Issues
Executive and Legislative initiatives to allow the biosimilars market place to succeed in the United States.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
Nathanson+Hauck filed a lobbying registration on Aug. 15, 2018 to represent Coherus Biosciences, effective Aug. 1, 2018.
Original Filing: 300980833.xml
Issue(s) they said they’d lobby about: Issues related to the development of a healthy biosimilars marketplace in the United States. .
1st Quarter, 2018
Nathanson+Hauck terminated an engagement in which they represented Coherus Biosciences on Jan. 2, 2018.
Original Filing: 300921055.xml
4th Quarter, 2017
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 2, 2018.
Original Filing: 300920989.xml
Lobbying Issues
Work to reconsider current CMS position on the structure of the Medicare J-Code for biosimilar medications.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
3rd Quarter, 2017
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Sept. 27, 2017.
Original Filing: 300900891.xml
Lobbying Issues
Work to reconsider current CMS position on the structure of the Medicare J-Code for biosimilar medications.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2017
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on July 13, 2017.
Original Filing: 300884300.xml
Lobbying Issues
S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications.
S.934 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications.
H.R. 2797 - FDA Reauthorization Act of 2017 - All issues related to the development and marketing of biosimilar medications.
Issues related to the treatment of biosimilar medications in Medicare Part B and D programs.
Issues related to the maintenance of current IPR laws.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications.
Issues related to the treatment of biosimilar medications in Medicare Part B and D programs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on April 17, 2017.
Original Filing: 300866488.xml
Lobbying Issues
S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications.
Issues related to the upcoming biosimilars User Fee Agreement legislation.
Issues related to the treatment of biosimilar medications in Medicare Part B and D programs.
Issues related to the maintenance of current IPR laws.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 771 - A bill to improve access to affordable prescription drugs - issues related to ensuring a healthy market for biosimilar medications.
Issues related to the treatment of biosimilar medications in Medicare Part B and D programs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 13, 2017.
Original Filing: 300846211.xml
Lobbying Issues
H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.
Issues related to Inter Partes Review and its role in ensuring a robust biosimilars market place.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Issues related to the treatment of Biosimilars in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have for the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Oct. 18, 2016.
Original Filing: 300829797.xml
Lobbying Issues
H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.
Issues related to Inter Partes Review and its role in ensuring a robust biosimilars market place.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Issues related to the treatment of Biosimilars in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have for the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on July 20, 2016.
Original Filing: 300816823.xml
Lobbying Issues
H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.
Issues related to Inter Partes Review and its role in ensuring a robust biosimilars market place.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Issues related to the treatment of Biosimilars in the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have for the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5054 - Agriculture Appropriations Bill for FY 2017- issues related to finding the Food and Drug Administration's Office of Biosimilars.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on April 14, 2016.
Original Filing: 300791561.xml
Lobbying Issues
FDA's March 31, 2016 Biosimilars Labeling Guidance.
Issues related to Inter Partes Review and its role in ensuring a robust biosimilars market place.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have for the Medicare and Medicaid programs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
FDA's March 31, 2016 Biosimilars Labeling Guidance.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States and the positive impact these medications will have on drug cost and access.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Nathanson+Hauck lobbied for Coherus Biosciences , earning $60,000. The report was filed on Jan. 5, 2016.
Original Filing: 300769254.xml
Lobbying Issues
H.R. 2029 - Consolidated Appropriations Act of FY 2016 - Provisions related to the treatment of biosimilars and the development of the marketplace in the United States.
CMS Proposed Physician Fee Schedule(PFS) with a focus on provisions dealing with the treatment of Medicare's reimbursement for a new class of prescription medications, Biosimilars.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2029 - Consolidated Appropriations Act of FY 2016 - Provisions related to the treatment of biosimilars and the development of the marketplace in the United States.
CMS Proposed Physician Fee Schedule(PFS) with a focus on provisions dealthing with the treatment of Medicare's reimbursement for a new class of prescription medications, Biosimilars.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
3rd Quarter, 2015
In Q3, Nathanson+Hauck lobbied for Coherus Biosciences , earning $20,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754651.xml
Lobbying Issues
CMS Proposed Physician Fee Schedule(PFS) with a focus on provisions dealthing with the treatment of Medicare's reimbursement for a new class of prescription medications, Biosimilars.
Education and advocacy related to what elements are necessary to ensure a hospitable environment to grow the new Biosimilars market in the United States.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...